论文部分内容阅读
目的研究聚乙二醇干扰素和利巴韦林对慢性丙型肝炎患者进行联合应用治疗后,患者获得快速病毒学免疫应答的预测因素。方法 120例慢性丙型肝炎患者,均接受了聚乙二醇干扰素和利巴韦林的联合治疗,治疗4周后,根据患者是否获得快速病毒学应答将其分为对照组(无快速病毒学应答)和观察组(有快速病毒学应答)。对比分析患者治疗前后相关情况,分析快速获得病毒学应答的因素。结果 120例患者中,91(75.83%)例患者有快速病毒学应答,29(24.17%)例患者无快速病毒学应答,且相关分析显示两组患者的年龄、感染时间、感染途径以及是否患有高血压等差异具有统计学意义(P<0.05)。结论慢性丙型肝炎患者在感染时间短、不含高血压疾病等情况下更容易快速获得病毒学应答。
Objective To investigate the predictors of rapid virological immune response in patients with peginterferon and ribavirin combined with chronic hepatitis C treatment. Methods A total of 120 patients with chronic hepatitis C were treated with combination therapy of peginterferon and ribavirin. After 4 weeks of treatment, they were divided into the control group according to whether the patients got rapid virological response (no rapid virus Learning response) and observation group (with rapid virological response). Comparative analysis before and after treatment of patients with relevant conditions, analysis of rapid virological response to the factors. Results Of the 120 patients, 91 (75.83%) had rapid virological response, 29 (24.17%) had no rapid virological response, and the correlation analysis showed the age, duration of infection, route of infection, Hypertension and other differences were statistically significant (P <0.05). Conclusions Patients with chronic hepatitis C are more likely to acquire rapid virological response with shorter duration of infection and no hypertensive disease.